Sirtris Pharmaceuticals (NASDAQ:SIRT)

When I pointed at Sirtris Pharmaceuticals in February I was considering to invest in that stock but had no money left. Too bad, since exactly happened what I had suggested: a big player is now trying to buy the company. GlaxoSmithKline today announced that it is going to acquire Sirtris (NASDAQ:SIRT) for $720 million through a cash tender offer of $22.50 per share.

More than 81% profit if you bought that stock yesterday.

US-Stocks viewed from the Eurozone

So far there was some money to be made with US-stocks. I myself made some with E*Trade (NASDAQ:ETFC) and Oracle (NASDAQ:ORCL) but less than I could’ve expected since the Dollar went down and down against other major currencies. That leads me to the idea that one should consider the exposure of certain stocks to export. Oracle sells a lot of its software and service to all parts of the world, E*Trade has branches in the Eurozone. Especially E*Trade with the momentarily low price seems to be a good re-investment for people in the Eurozone or Yen: the stock price in US-Dollars now is somewhat 10% lower that 2 months ago at the same levels. Someone investing in Euro has either lost 10% or can re-invest 10% cheaper now.

The question is: will the Dollar go lower or not?

I’d say, the risk of going much lower is far more unlikely than going up. This means, buying US-stocks now could bring a lot more profit than risking a lot. Especially with cheap stocks like E*Trade. Honestly: the bankruptcy-szenario of Prashant Bhatia is gone with the wind and a single act (or a unique chance seen from today’s point of view). No one will listen to this guy and his fantastic analytics anymore …

However, E*Trade remains a good investment for long – but also for fast money since the volatility will keep up.